Triclabendazole
Clinical data | |
---|---|
Trade names | Fasinex, Egaten, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a619048 |
License data | |
QP52AC01 (WHO) | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Oxidation to sulfone and sulfoxide metabolites |
Elimination half-life | 22–24 hours |
Excretion | Feces (>95%), urine (2%), milk (<1%) |
Identifiers | |
| |
JSmol) | |
Melting point | 175 to 176 °C (347 to 349 °F) |
| |
| |
(what is this?) (verify) |
Triclabendazole, sold under the brand name Egaten among others, is a medication used to treat
fascioliasis and paragonimiasis.[1] It is very effective for both conditions.[1] Treatment in hospital may be required.[1] It is taken by mouth with typically one or two doses being required.[1]
Side effects are generally few, but can include abdominal pain and headaches.medications for worms.[1]
Triclabendazole was approved for medical use in the United States in 2019.[3][4] It is on the World Health Organization's List of Essential Medicines.[5] For human use, it can be obtained from the World Health Organization.[2] It is also used in animals.[6]
Chemistry
It is a member of the
microtubules.[citation needed
]
History
Since late 1990s, triclabendazole became available as a
roundworms and ectoparasites, as well.[citation needed
]
Fasinex is a brand name for veterinary use while Egaten is a brand name for human use.[citation needed]
References
- ^ ISBN 9789241547659.
- ^ ISBN 9781118481554. Archivedfrom the original on 20 December 2016.
- ^ "Drug Trials Snapshots: Egaten". U.S. Food and Drug Administration (FDA). 13 February 2019.
- ^ "Egaten (triclabendazole)" (PDF). FDA. Retrieved 18 February 2019.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ "Triclabendazole". Drugs.com. Archived from the original on 20 December 2016. Retrieved 10 December 2016.